John Boniface
Chief Tech/Sci/R&D Officer at SERA PROGNOSTICS, INC.
Net worth: 1 M $ as of 2024-03-30
Profile
John J.
Boniface is currently the Chief Scientific Officer at Sera Prognostics, Inc. He previously worked as a Program Director at Myriad Genetics, Inc., Myrexis, Inc., EOS Biotechnology, Inc., and Prolexys Pharmaceuticals, Inc. He also served as Vice President-Science at Bioinformatics Solutions, Inc. Boniface received his undergraduate degree from the University of Massachusetts and his doctorate from Albany Medical College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-27 | 139,771 ( 0.44% ) | 1 M $ | 2024-03-30 |
John Boniface active positions
| Companies | Position | Start |
|---|---|---|
| SERA PROGNOSTICS, INC. | Chief Tech/Sci/R&D Officer | 2011-10-31 |
Former positions of John Boniface
| Companies | Position | End |
|---|---|---|
Bioinformatics Solutions, Inc.
 Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Chief Tech/Sci/R&D Officer | - |
EOS Biotechnology, Inc.
 EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Corporate Officer/Principal | - |
| MYRIAD GENETICS, INC. | Corporate Officer/Principal | - |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - |
| MYREXIS, INC. | Corporate Officer/Principal | - |
Training of John Boniface
| University of Massachusetts | Undergraduate Degree |
| Albany Medical College | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| MYREXIS, INC. | Finance |
| SERA PROGNOSTICS, INC. | Health Services |
| Private companies | 3 |
|---|---|
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Technology Services |
- Stock Market
- Insiders
- John Boniface
